Skip to Main

David is the leader of Boston Consulting Group's Health Care practice in Switzerland and has worked extensively with clients in the pharmaceutical and biotech industries in Europe, the US, and emerging markets.

David collaborates with clients on a broad range of strategic and operational topics including commercial, market access, medical affairs, R&D, corporate strategy, and large-scale transformations.

Prior to joining our Zurich office, David conducted doctoral research in molecular biotechnology, focusing on gene control and delivery applications for recombinant protein production and therapeutic use.

AREAS OF EXPERTISE

EDUCATION

  • PhD, Swiss Federal Institute of Technology (ETH), Zurich
  • LLB, honors, Australian National University
  • BSc , honors, , Australian National University

HONORS AND AWARDS

  • University Medal, Australian National University

Publications and Videos

agile-in-pharma-rectangle-opt.jpg

Agile Can Work Wonders in Pharma

Even highly regulated and rigid industries can benefit from new ways of working.
r-and-d-productivity-2014-1694x950-tcm9-79958.jpg

R&D Productivity 2014: A Breakthrough Year for Biopharma

R&D productivity has been declining for decades, but a record 53 new therapeutic drugs approved by the U.S. FDA in 2014 suggest that the biopharma industry's fortunes have changed.
challenge-pricing-combination-1694x950-tcm9-81462.jpg

The Challenge of Pricing Combination Therapies

Pharmaceutical companies are seeking approval of more combination therapies, but setting prices for the various products that make up those treatments is exceedingly complex.